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Abstract
Background: Gene trap insertional mutagenesis was used as a high-throughput approach to discover cellular
genes participating in viral infection by screening libraries of cells selected for survival from lytic infection with a
variety of viruses. Cells harboring a disrupted ADAM10 (A Disintegrin and Metalloprotease 10) allele survived
reovirus infection, and subsequently ADAM10 was shown by RNA interference to be important for replication of
HIV-1.
Results: Silencing ADAM10 expression with small interfering RNA (siRNA) 48 hours before infection significantly
inhibited HIV-1 replication in primary human monocyte-derived macrophages and in CD4
+ cell lines. In agreement,
ADAM10 over-expression significantly increased HIV-1 replication. ADAM10 down-regulation did not inhibit viral
reverse transcription, indicating that viral entry and uncoating are also independent of ADAM10 expression.
Integration of HIV-1 cDNA was reduced in ADAM10 down-regulated cells; however, concomitant 2-LTR circle
formation was not detected, suggesting that HIV-1 does not enter the nucleus. Further, ADAM10 silencing
inhibited downstream reporter gene expression and viral protein translation. Interestingly, we found that while the
metalloprotease domain of ADAM10 is not required for HIV-1 replication, ADAM15 and g-secretase (which
proteolytically release the extracellular and intracellular domains of ADAM10 from the plasma membrane,
respectively) do support productive infection.
Conclusions: We propose that ADAM10 facilitates replication at the level of nuclear trafficking. Collectively, our
data support a model whereby ADAM10 is cleaved by ADAM15 and g-secretase and that the ADAM10 intracellular
domain directly facilitates HIV-1 nuclear trafficking. Thus, ADAM10 represents a novel cellular target class for
development of antiretroviral drugs.
Background
Cell homeostasis and ordered proliferation require the
interaction of cellular elements that can be assigned to
functional pathways. While cells have partial redundancy
and regulated expression of components of important
cellular pathways, simple pathogens such as viruses
appear to be restricted in their interactions. Based upon
the hypothesis that disruption of specific cellular pro-
teins would still allow cell and host survival but restrict
or inhibit pathogen replication, we have randomly dis-
rupted cellular genes with an insertional mutagen and
selected for candidate genes whose inactivation allows
cell survival following lytic infection. Previously, we
reported this strategy was successful in the discovery of
several critical host genes, including components of the
IGF-II pathway for reovirus and Rab9 for Marburg
virus, validating the initial hypothesis [1-3]. Moreover,
we reasoned that viruses evolved from common ances-
tral archetypes might exhibit conserved viral-host pro-
tein-protein interactions. Thus, we tested whether
candidate genes discovered had broad capability to facil-
itate replication of viruses from other families and found
that disruption of the Rab9 pathway also limited the
replication of Ebola virus, measles virus, and HIV-1 [1].
HIV-1 replication requires the assistance of multiple
host cell functions for productive infection and several
participating cellular factors have been identified. Recent
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host factors that participate in a broad array of cellular
functions and implicate new pathways in the HIV-1 life
cycle [4-8]. Host cell encoded factors are required dur-
ing every step of virus replication, with the possible
exception of initiation of reverse transcription [9-12].
We identified A Disintegrin And Metalloprotease 10
(ADAM10) in a gene trap library selected for resistance
to lytic infection with reovirus and subsequently found
that ADAM10 expression is critical for HIV-1 replica-
tion. ADAM10 is a cellular metalloprotease that acti-
v a t e sn u m e r o u sa n dd i v e r s ec e l l u l a rp r o t e i n sv i a
proteolytic cleavage. In addition to its metalloprotease
domain, it also contains a disintegrin domain, an EGF-
like domain, a cysteine-rich domain, a transmembrane
domain, and a cytoplasmic domain [13]. ADAM10 is
required in NOTCH signaling during embryogenesis
[14]. It also shares some functions with ADAM17 in the
cleavage and release of surface bound TNF-a,E - c a d -
herin, and other proteins [15-20]. Previous studies have
indicated that ADAM10 is found in both the cellular
and nuclear membranes [21,22]. It has been shown that
a released intracellular fragment (ICF) of ADAM10 is
capable of translocating into the nucleus and is poten-
tially important in the nuclear transport of the androgen
receptor [21]. Tousseyn and colleagues have shown that
this nuclear entry of ADAM10 is dependent upon
sequential proteolytic modification, and demonstrated
that the ectodomain of ADAM10 is first shed by either
ADAM9 or ADAM15 and the intracellular domain is
subsequently cleaved by g-secretase, releasing the ICF
[23].
In studies reported herein, it was found that transfect-
ing cells with ADAM10 small interfering RNA (siRNA)
dramatically inhibited replication of X4 and R5 HIV-1
strains, both in primary human monocyte-derived
macrophages and in CD4
+ cell lines. Moreover, our data
indicate that ADAM10 is critical for post-entry HIV-1
replication events occurring during nuclear trafficking
or nuclear entry in human monocyte-derived macro-
phages and in CD4
+ cell lines, and is dependent upon
its proteolytic modification. Furthermore, we show that
ADAM15 and g-secretase are also required for HIV-1
replication, suggesting that the ADAM10 intracellular
domain (ICD) is required for nuclear trafficking of
HIV-1 to the nucleus.
Results
Implication of ADAM10 in reovirus replication using gene
trap insertional mutagenesis
We have applied gene trap insertional mutagenesis
[1-3,24] as a high throughput genetic screen to aid in
the discovery of novel genes critical for viral replication.
Cellular alleles are randomly inactivated, and cells sur-
viving an otherwise toxic viral infection harbor a
mutated gene, whose wild type counterpart is potentially
utilized in the viral life cycle [1,3]. To identify targets
for broad-spectrum viral inhibition, we determined
whether candidate genes implicated in gene trap studies
with unrelated viruses serve a functional role in HIV-1
replication. Small interfering RNA (siRNA) was used to
knockdown expression of candidate genes, and the effect
on HIV infection was determined by assaying HIV-1 p24
production. HeLa cells modified to stably express CD4
and CCR5 (TZM-bl cells) were screened with siRNAs
targeting genes trapped with reovirus, influenza A, or
Marburg virus 48 h prior to infection with LAV (X4-tro-
pic). Treatment of TZM-bl cells with siRNA specific for
ADAM10 inhibited HIV-1 replication ~90% (n = 4, data
not shown). We also observed that siRNA targeting
ERBB2IP did not affect HIV-1 replication, and thus was
also used in these studies as a negative control.
ADAM10 silencing inhibits both R5- and X4-tropic HIV-1
replication
To confirm the requirement of ADAM10 in more phy-
siologically relevant primary cells, human blood-derived
macrophages were transfected with siRNAs targeting
A D A M 1 0 ,C D 4 ,o rw i t has c r a m b l e ds e q u e n c ec o n t r o l
siRNA, and then infected with the R5 HIV-1 strain
SF162. Figure 1A shows that ADAM10 silencing effec-
tively inhibited R5-tropic HIV-1 replication when
human monocyte-derived macrophages were transfected
with siRNAs 48 h prior to infection. ADAM10 siRNA
inhibition of HIV-1 was similar to that seen with siRNA
directed against CD4, the primary cellular receptor for
HIV-1 [25].
Interestingly, ADAM10 silencing also inhibited repli-
cation of the X4-tropic LAV strain in CD4
+ TZM-bl
cells (Figure 1B). ADAM17 is a related metalloprotease
which shares partial (but not complete) substrate speci-
ficity with ADAM10 [15-20], and has been shown to
mediate SARS-CoV envelopes h e d d i n g[ 2 6 ] .A c c o r d -
ingly, the role of ADAM17 expression in HIV-1 replica-
tion was studied by knockdown of expression with
RNAi in TZM-bl cells; however, ADAM17 silencing did
not significantly inhibit viral replication. These results
indicate that ADAM10, but not ADAM17, serves a
specific role in the viral lifecycle.
ADAM10 silencing for one week does not affect
macrophage viability or function
ADAM10 siRNA transfectants were confirmed to have
significant reductions in ADAM10 protein expression by
both flow cytometry in cell lines 48 h after siRNA trans-
fection (Figure 2A) and Western blot analysis in primary
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Kinetics of ADAM10 mRNA down-regulation by siRNA
was measured using real time PCR in U373-MAGI-CCR5
cells (Figure 2C) and primary human macrophages
(Figure 2D). To determine the viability of siRNA-trans-
fected macrophages, cytotoxicity was assayed using
GAPDH coupled to 3-phosphoglyceric phosphokinase
and measuring ATP [27]. The siRNA transfections
resulted in no significant adverse cytotoxic effect (P <
0.01), although dose-dependent cell death was observed
when cells were treated with chelerythrine, a Protein
Kinase C inhibitor (data not shown). In addition,
ADAM10 siRNA-transfected macrophages displayed
phagocytic function similar to macrophages transfected
with scrambled siRNA, as determined by comparing the
phagocytosis of captured bodipy beads [28] (data not
shown).
ADAM10 expression is not required for HIV-1 reverse
transcription
To determine whether ADAM10 is required for entry or
HIV-1 reverse transcription, small non-genomic DNA
was isolated from control- and ADAM10 siRNA-trans-
fected macrophages at 48 h post-infection for quantifi-
cation by real-time PCR. Previous studies demonstrated
that kinetics of reverse transcription is slower in macro-
phages than in lymphoid cells, and full-length HIV-1
reverse transcripts are not generated until 36-48 h after
infection in macrophages [29,30]. Thus, cDNA levels
detected at 48 hours post-infection should be reflective
of only a single replication cycle. As shown in Figure
3A, ADAM10 silencing did not affect detection of full
length HIV-1 cDNA, whereas viral DNA formation was
not detected in cells treated with the reverse transcrip-
tion inhibitor AZT. These data demonstrate that
ADAM10 expression is not required for HIV-1 entry
and completion of reverse transcription.
ADAM10 activity in HIV-1 replication precedes viral
integration
To determine if ADAM10 is required for proviral DNA
integration, genomic and small non-genomic cDNA was
isolated from cells at various time points post-infection.
If HIV-1 cDNA enters the nucleus but does not inte-
grate into the host cell chromosome, then the viral
cDNA circularizes to form a 2-LTR circle [31,32], which
can be quantified using real-time PCR. Integration is
quantified by using one primer directed against HIV-1
and another primer directed against Alu, a common
repetitive sequence found in the human genome.
Knockdown of ADAM10 significantly reduces the
amount of integrated HIV-1 cDNA in both macro-
phages (Figure 3B) and U373-MAGI-CCR5 cells
(Figure 3C). Small non-genomic DNA was isolated from
cells after infection to quantify formation of 2-LTR cir-
cles. As shown in Figure 3D, 2-LTR circle formation
was not observed in macrophages treated with siRNA to
ADAM10, whereas when cells were treated with the
integrase inhibitor, Raltegravir, 2-LTR circles are
detected [33]. Inhibition of both HIV-1 integration and
2-LTR circle formation by ADAM10 siRNA indicates
that while HIV-1 cDNA is efficiently generated, it is not
efficiently translocated into the nucleus of ADAM10
down-regulated cells.
ADAM10 is utilized for steps prior to HIV-1 tat expression
To confirm that ADAM10 function is not required for
HIV-1 replication events following integration, U373-
MAGI-CCR5 cells were used in reporter gene assays to
gauge the effect of ADAM10 silencing on Tat function.
Tat function was measured by b-galactosidase (b-gal)
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Figure 1 ADAM10 silencing inhibits both CCR5- and CXCR4-
tropic HIV-1 replication.( A) Primary macrophages were
transfected with different siRNAs 48 h prior to infection with HIV-
SF162. Azidothymidine (AZT) treatment was used as a positive
control to block infection. Supernatants were collected 7 days after
infection and HIV p24 production was measured by ELISA. ADAM10
silencing significantly reduced viral replication in primary human
macrophages (**P < 0.01). (B) To determine whether ADAM17 also
plays a role in HIV-1 replication, TZM-bl cells were transfected with
ADAM17, ADAM10 or ERBB2IP siRNAs 48 h prior to infection with
LAV, and supernatant HIV p24 was measured by ELISA 3 days after
infection (*P < 0.05).
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Figure 2 ADAM10 silencing persists for one week following siRNA transfection. Assessment of ADAM10 expression following RNAi by
(A) flow cytometry in TZM-bl cells 48 hours after transfection, (B) Western blot in primary human macrophages 48 hours after transfection, and
real time PCR in (C) U373-MAGI-CCR5 cells and (D) primary human macrophages at various times after siRNA transfection. Relative levels of
ADAM10 mRNA expression in siRNA transfectants were normalized to GAPDH expression (n = 4).
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Page 4 of 14activity expressed from a stably integrated HIV-LTR-b-
gal construct [34]. As shown in Figure 4A, Tat activity
was robust in ERBB2IP control siRNA-transfected and
HIV-1 infected, but not transfected (virus only), cells at
72 h. Tat activity in ADAM10 or CD4 siRNA-transfec-
tants at 72 h post-infection was similar to the back-
ground levels seen at Day 0. However, Tat activity was
unaffected by ADAM10 silencing when U373-MAGI-
CCR5 cells were transfected with a plasmid encoding
recombinant Tat (Figure 4B), indicating that ADAM10
does not directly activate Tat and that ADAM10 affects
virus replication prior to Tat transcription or transla-
tion. In agreement, Western blots revealed that produc-
tion of the viral Env and p24 proteins were significantly
inhibited between days 4-7 post-infection in primary
macrophages following ADAM10 silencing (data not
shown).
Additionally, the role of ADAM10 was studied in
TZM-bl cells transfected with a plasmid-based molecular
clone (pNL4-3) or infected with the corresponding HIV-
NL4-3 virus. Although replication of HIV-NL4-3 was
dramatically inhibited in ADAM10 siRNA-transfectants,
ADAM10 was not required in the plasmid-based system
(Figure 4C). The pNL4-3 plasmid has a 15 kb insert that
includes a full-length proviral clone and one to two kb of
flanking cellular sequence outside both the 5’ and 3’ LTR
and very efficiently directs HIV gene expression following
transfection, independent of plasmid integration. Thus,
the plasmid serves as a surrogate for proviral integration,
bypassing the normal early events of the viral life cycle
(Figure 4D). Additionally, we used a U1 cell line, which
contains two integrated copies of the HIV-1 proviral
genome, and can be induced to produce progeny
virus following treatment with a phorbol ester [35,36].
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Figure 3 HIV-1 nuclear entry, but not completion of reverse transcription, is affected by ADAM10 down-regulation.( A) Primary human
macrophages were transfected with either ADAM10 or ERBB2IP siRNA 48 h prior to infection with HIV-SF162. DNA was isolated 48 h after
infection and real time PCR was used to quantitate formation of full length HIV cDNA. In order to amplify HIV cDNA with these full length
primers, two template-switching events and continuous 5’LTR and gag sequences must be present on either strand, which is the last event to
occur during HIV reverse transcription [79]. (B, C) Integration of HIV was significantly lower in ADAM10 down-regulated (B) primary human
macrophages and (C) U373-MAGI-CCR5 cells than in control ERBB2IP down-regulated cells following infection with HIV-SF162. Genomic DNA was
used to quantitate integrated HIV cDNA using real-time PCR using primers specific for integrated HIV cDNA. (D) 2-LTR circle formation in
ADAM10 down-regulated macrophages was significantly less than that seen in macrophages treated with the integrase inhibitor raltegravir, and
was similar to infected but untreated cells. Formation of 2-LTR circles was quantitated by real-time PCR [80]. (No Inf = No Infection, Ral =
Raltegravir, Scr = Scrambled siRNA, **P < 0.01).
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tion of HIV-1 in these cells (data not shown). These data
indicate that ADAM10 supports virus replication prior to
gene transcription. Taken together, these data suggest
that the function of ADAM10 in HIV-1 replication is
bracketed between the levels of nuclear trafficking and
nuclear entry.
A functional ADAM10 metalloprotease is not
required for HIV-1 replication
To determine whether over-expression of ADAM10
increases HIV-1 replication and infection, we obtained a
human ADAM10 plasmid from Dr. Stefan Lichtenthaler
(LMU Munich, Germany). As shown in Figure 5A, over-
expression of ADAM10 resulted in increased HIV-1
replication. The metalloprotease domain potentially
responsible for this increase was further investigated.
ADAM10 E384A plasmid contains a single inactivating
point mutation in the metalloprotease domain rendering
the metalloprotease domain inactive [37]. ADAM10
E384A and wild type (wt) ADAM10 plasmids were
transfected into U373-MAGI-CCR5 cells 48 h prior to
infection with HIV-SF162 (MOI = 0.1). As shown in
Figure 5B, over-expression of ADAM10 E384A showed
an increase in HIV-1 replication very similar to that
seen with wt ADAM10 over-expression, suggesting that
the metalloprotease domain is not the critical domain in
ADAM10 supporting HIV-1 infection. In addition, tissue
Figure 4 ADAM10 down-regulation inhibits Tat-dependent HIV-1 replication steps.( A) ADAM10 down-regulation with siRNA affects Tat-
dependent b-galactosidase production in U373-MAGI-CCR5 cells after infection with HIV-SF162. b-galactosidase was measured by fluorescence at
various time points after infection (**P < 0.01). (B) ADAM10 does not directly activate Tat. After either ADAM10 or ERBB2IP down-regulation,
U373-MAGI-CCR5 cells were transfected with a plasmid encoding recombinant Tat, indicating that ADAM10 affects virus replication prior to Tat
transcription or translation. b-galactosidase is expressed as RLUs (Relative Light Units). (C) ADAM10 down-regulation significantly reduces HIV p24
production in virally infected but not HIV plasmid-transfected TZM-bl cells. ADAM10 down-regulation affected viral replication in HIV-NL4-3
infected cells, but not in cells transfected with pNL4-3, a plasmid expressing the full length NL4-3 molecular clone (*P < 0.05) (D) Diagram
illustrating the different processes for virus production in the virus vs plasmid experiment. Viral mRNA can be directly transcribed from the pNL4-
3 plasmid, while virus infection must go through entry, reverse transcription, nuclear entry, and integration to produce viral RNA.
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have been shown to inhibit ADAM10 metalloprotease
activity [38], had no effect on HIV-1 replication in
human macrophages (Figure 5C, D). This indicates that
the ADAM10 metalloprotease domain is not function-
ally required for HIV-1 replication.
Both g-secretase and ADAM15 are required for HIV-1
replication
To determine if the intracellular domain of ADAM10
plays a role in HIV-1 replication, we independently
inhibited the two necessary proteolytic steps that free
this fragment. ADAM9 and ADAM15 were shown to
cleave the ectodomain of ADAM10 while g-secretase
has been shown to cleave and release the ADAM10
intracellular domain (ICD) [23]. Once released, the
ADAM10 ICD can then translocate to the nucleus or
peri-nuclear region [21,23]. To determine whether
ADAM9 and/or ADAM15 were required for HIV-1
replication, cells were transfected with siRNAs directed
against either ADAM9 or ADAM15 mRNA prior to
infection. As shown in Figure 6A, ADAM15 siRNA sig-
nificantly reduced HIV-1 replication, comparable to the
level of replication seen with knockdown of ADAM10,
whereas ADAM9 knockdown had no effect on HIV-1
replication. Next, we studied the role of g-secretase, a
multi-subunit complex, containing presenilin, nicastrin,
anterior pharynx-defective 1 (APH-1), and presenilin
enhancer protein 2 (PSEN) [39], in HIV-1 replication. g-
secretase contains either the presenilin-1 (P1) or prese-
nilin-2 (P2) isoform, which contributes to the substrate
specificity of the enzyme [40]. To determine if g-secre-
tase is required for HIV-1 replication, siRNA targeting
different components of g-secretase was used to inhibit
the enzyme. As shown in Figure 6B, siRNA targeting P2,
nicastrin, and PSEN all significantly decreased HIV-1
replication in U373 cells. However, P1 siRNA did not
affect HIV-1 replication. These data show a specific role
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Figure 5 A functional ADAM10 metalloprotease domain is not required for HIV-1 replication.( A) Over-expression of wt ADAM10 in U373-
MAGI-CCR5 cells increased HIV-1 replication; however, cell toxicity was noted at concentrations of 0.5 μg and above. b-galactosidase activity was
measured 48 h after infection (*P < 0.05, **P < 0.01). (B) Over-expression of wt ADAM10 and ADAM10 E384A both increased HIV-1 replication
U373-MAGI-CCR5 cells. 0.5 μg of DNA plasmid was transfected into U373 cells and infected with HIV-SF162 48 hours after transfection. Cells were
lysed and b-galactosidase activity was measured 48 h after infection (*P < 0.05). (C) Serial dilutions of tissue inhibitors of metalloprotease 1
(TIMP-1) were added to primary macrophages, and cell viability was assessed 24 h after addition of TIMP-1. (D) TIMPs had no effect on HIV-1
replication in primary human macrophages. TIMPs (25 nM) were added to primary macrophages 24 h prior to and during infection with HIV-
SF162. Supernatant was collected 7 d after infection and HIV-1 p24 production was measured by ELISA.
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tion. Additionally, we used specific g-secretase inhibi-
tors, L-685,458 and DAPT [41,42]. Cytotoxicity assays
were performed to determine optimal, sub-toxic concen-
trations for either inhibitor (Figure 6C). Figure 6D
shows that adding 10 μM of either L-685,458 or DAPT
to U373 cells 24 h prior to infection and during infec-
tion, significantly decreased HIV-1 replication as com-
pared to DMSO-only treatment and infection only
controls. These findings confirm that g-secretase is
required for HIV-1 replication. Taken together, both
ADAM15 and g-secretase facilitate HIV-1 replication,
consistent with their roles in the release of the
ADAM10 intracellular domain.
Discussion
We utilized gene-entrapment of diploid cell lines for our
initial selection of candidate genes associated with cell
survival following lytic virus selection. Several possible
outcomes may result, including haploid insufficiency,
complete loss of expression from a vector inserted into
a dominant allele [43-45], or dominant negative effects
due to truncated translational products [46,47]. Further-
more, siRNA can be used as a confirmatory step across
a wide variety of cell types and viruses, once a candidate
gene is identified, as we reported for HIV-1 infection
[1]. In this study, we identified ADAM10 by gene trap
insertional mutagenesis as a disrupted gene in cells sur-
viving cytolytic reovirus infection, and we demonstrated
the importance of ADAM10 expression at a post-entry
step in HIV-1 replication. We also show that over-
expression of ADAM10 increases HIV-1 replication.
Interestingly, in previous studies solely using siRNA or
shRNA to identify cellular proteins required for HIV-1
replication [4-7], Brass et al. had also identified
ADAM10 as a required cellular gene [4]. Importantly,
these studies show that ADAM10 silencing inhibits
HIV-1 in primary human macrophages, which are more
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Figure 6 ADAM15 and g-secretase are required for HIV-1 replication.( A) ADAM15 downregulation significantly reduced HIV-1 replication in
U373-MAGI-CCR5. However, ADAM9 downregulation did not affect HIV-1 replication. U373 cells were transfected with siRNA and b-galactosidase
was measured 48 h after infection with HIV-SF162. (B) Down-regulation of g-secretase subunits significantly decreased HIV-1 replication.
Presenilin-2, not presenilin-1, is specifically required for HIV-1 replication (P1 = presenilin-1, P2 = presenilin-2, PSEN = presenilin enhancer protein
2, **P < 0.01). b-galactosidase was measured 48 h after infection with HIV-SF162. (C) Serial dilutions of g-secretase inhibitors (L-685,458 and
DAPT) were added to the cells, and cell viability was assessed 24 h after addition of inhibitors. (D) L-685,458 and DAPT significantly reduced b-
galactosidase in U373-MAGI-CCR5 cells compared to DMSO controls. b-galactosidase activity was measured 48 h after infection with HIV-SF162
(**P < 0.01).
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cell lines [48]. Macrophages and CD4
+ lymphocytes are
the predominant cell types infected with HIV-1 clini-
cally, and the importance of ADAM10 in HIV-1 replica-
tion in primary human macrophages supports a role of
ADAM10 in HIV-1 pathogenesis.
To determine the precise step in HIV-1 replication in
which ADAM10 participates, we inhibited various pro-
cesses and queried for viral products that define steps
up to and including virus expression from chromoso-
mally integrated viral DNA. Our data supports a role for
ADAM10 at a step in virus replication prior to integra-
tion. HIV-1 must enter the cell and be partially disas-
sembled prior to reverse transcription of viral cDNA,
and these steps are not inhibited with knockdown of
ADAM10. It was found that ADAM10 silencing resulted
in a failure of viral cDNA to integrate, as measured by
real time PCR. Moreover, HIV-1 2-LTR circles did not
accumulate in the nucleus, which occurs after virus
enters the nuclear membrane but cannot integrate. It is
known that 2-LTR circles accumulate when integration
is inhibited with specific integrase enzyme inhibitors
[33]. Furthermore, ADAM10 silencing did not affect
Tat-dependent proviral gene expression as assessed in
studies using a plasmid expressing Tat and Tat-depen-
dent b-galactosidase expression. Using pNL4-3, a plas-
mid containing the HIV-1 genome, knockdown of
ADAM10 did not limit virus transcription, consistent
with its role prior to viral transcription from integrated
proviral DNA. Our data are supportive of an important
role for ADAM10 in HIV-1 replication at a step follow-
ing reverse transcription but prior to HIV-1 integration,
likely at the level of nuclear trafficking.
A role for ADAM10 during nuclear trafficking is in
concert with known cellular roles for this complex pro-
tein. The protein has several known extracellular
domains, which include a metalloprotease domain, an
integrin binding domain, and a cysteine rich region. A
recent study has shown ADAM10 to be essential for
cell entry of Plasmodium falciparum due to its interac-
tion with the malaria PfSUB2 enzyme [49]. ADAMs
function in the proteolytic release of many transmem-
brane cell surface cytokines, growth factors, receptors,
and adhesion proteins, a process known as ectodomain
shedding. ADAM10 is known to cleave over 20 cell
surface proteins [15-20,50-68]. Most known ADAM10
substrates are involved in cellular adhesion, including
ephrin-A2 (EFNA2), AXL, fractalkine (CX3CL1),
CXCL16, E- and N-cadherin (CHD1 and 2), the g-pro-
t o c a d h e r i n sC 3a n dB 4 ,N C A M ,C H L 1 ,L A G - 3 ,C D 2 3 ,
CD44, CD46, and desmoglein-2 (DSG2). However,
while there is known promotion of trans-infection of
HIV-1 secondary to interaction with the adhesion
molecules, C-type lectins DC-SIGN and DC-SIGNR
[69,70], the data presented above do not support a role
in cell entry for ADAM10. Surprisingly, the metallo-
protease function was not required for HIV-1 replica-
tion. More recently, activity has been attributed to the
6 kDa fragment released from the carboxy-terminus.
This fragment is released from the intracellular domain
following sequential proteolytic digestion. ADAM9 and
-15 have been shown to be responsible for releasing
the ADAM10 ectodomain, while presenilin/g-secretase
has been shown to be responsible for the proteolytic
release of the ADAM10 intracellular domain from the
plasma membrane, whereupon it localizes to the
nucleus [23]. Cleavage and release of the ADAM10
ectodomain are required for the intracellular domain
to be subsequently released. We demonstrate that both
ADAM15 and g-secretase are required for HIV-1 repli-
cation, which strongly suggests the intracellular domain
of ADAM10 is critical for HIV-1 replication. We did
not find ADAM9 to be required for HIV-1 replication
in our assays. Whether this is unique to the cell line
used in our assays, as ADAM10 can be alternatively
spliced, or rather that ADAM15 is specifically required
by HIV-1, requires further study.
Conclusions
ADAM10 has a role in androgen receptor nuclear trans-
location and has been shown to translocate to the
nuclear and the perinuclear region during prostate can-
cer pathogenesis and progression [21]. Combined with
our data showing that ADAM10 functions during
nuclear trafficking or nuclear entry, we suggest that the
intracellular domain may either function to promote
trafficking of HIV-1 PIC to the nucleus (Figure 7), or
serve a scaffolding role during PIC assembly. The rela-
tionship between ADAM10 intracellular domain and
HIV-1 PIC needs further study. It is possible that the
ICD directly interacts with HIV-1 viral proteins or
nucleic acid, or it is essential for another host compo-
nent that traffics the PIC through the nuclear pore. Stu-
dies are ongoing to determine its precise role in HIV-1
entry into the nucleus. It is intriguing to note that
ADAM10 is not the only ADAM protein that has dual
functionality, as Cousin et al.h a v ef o u n dt h a tt h e
nuclear translocation of the ADAM13 intracellular
domain is required for gene expression and neural crest
cell migration [71]. Whether this class of proteins parti-
cipates in the replicative cycle for other virus may
deserve further study.
These studies utilized both primary human macro-
phages and tissue culture adapted cell lines that have
been extensively used in the study of HIV-1. Primary
macrophages with knockdown of ADAM10 were viable
and functionally active, thereby raising the possibility
that inhibition of ADAM10 processing or targeting the
Friedrich et al. Retrovirology 2011, 8:32
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therapeutic targets.
Methods
Cells, viruses, and reagents
Monocyte-derived human macrophages were prepared
from leukopaks obtained from the University of Texas
Medical Branch Blood Bank (Galveston, TX). Peripheral
blood mononuclear cells were recovered from leukopaks
by Ficoll-Hypaque density centrifugation and were puri-
fied by adherence to plastic, as previously described
[72]. The following cell lines were obtained from the
NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH: CD4/CCR5/CXCR4
+
TZM-bl HeLa cells from Dr. John C. Kappes, Dr.
Xiaoyun Wu and Tranzyme Inc. [73]; U373-MAGI-
CCR5 cells (contributed by Dr. Michael Emerman and
Dr. Adam Geballe), are a cell line derived from a glio-
blastoma that has been modified by stable transfection
of LTR-b-galactosidase which is trans-activated by HIV
Tat in relation to the level of virus replication [74].
U373-MAGI-CCR5 cells also express CD4 and human
chemokine receptor CCR5 to enable infection by HIV
R5 strains and were maintained in Dulbecco’s modified
Eagle’sm e d i u m( D M E M )s u p p l e m e n t e dw i t h1 0 %F B S ,
0.2 mg/mL G418, 0.1 mg/mL hygromycin, and 1.0 μg/
mL puromycin [75]. Rat intestinal epithelial 1 (RIE-1)
cells were maintained in DMEM supplemented with
10% FBS, penicillin, and streptomycin. Primary R5
viruses HIV-SF162 [76] and HIV-SX [72] were pur-
chased from the Virology Core Facility, Center for AIDS
Research at Baylor College of Medicine, Houston, TX.
HIV-SX stock containing 69.681 ng/ml of HIV p24 with
6.5 × 10
4 TCID50/ml and HIV-SF162 stock containing
169 ng/ml of HIV p24 with 4.2 × 10
5 TCID50/ml were
used for macrophage and U373 infection experiments at
an MOI of 0.1. The following reagents were obtained
through the AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, NIH: pNL4-3 from Dr.
Malcolm Martin [77] and HIV-LAV [78]. TZM-bl cells
PIC
Ȗ-secretase
Nucleus
HIV-1
ADAM10
Uncoating
Entry
Nuclear Trafficking
Integration
extracellular
intracellular
ICD
ICD = Intracellular domain
PIC = Pre-integration Complex
ICD
ADAM15
Nuclear Entry
Figure 7 Hypothesized role for ADAM10 during HIV-1 replication, affecting nuclear trafficking. ADAM15 cleaves the ADAM10 extracellular
domain, followed by cleavage of the ADAM10 intracellular domain (ICD) by g-secretase. Data presented in this study support a model whereby
release of the ADAM10 ICD from the plasma membrane facilitates HIV-1 replication, either by promoting trafficking/docking of the HIV-1 pre-
integration complex (PIC) to the nuclear membrane, or PIC translocation into the nucleus.
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tious NL4-3 virus, an X4 HIV-1 strain. TIMPs were pur-
chased from R&D Systems, Inc. (Minneapolis, MN
55413). L-685,458 and DAPT were purchased from
Sigma-Aldrich (St. Louis, MO).
siRNA transfections
siRNA SMARTpools targeting candidate host mRNAs
were synthesized by Dharmacon (Lafayette, CO). Indivi-
dual siRNA duplexes targeting ADAM10 mRNA were
against positions 1119-1138 (5’ CCCAAAGTCTCT
CACATTA-3’), 1272-1280 (5’-GGACAAACTTAAC
AACAAT-3’), 1591-1609 (GCAAGGGAAGGAA-
TATGTA-3’), and 2070-2088 (5’-GCTAATGGCTGG
ATTTATT-3’). TZM-bl and U373 cells were transfected
with Lipofectamine 2000 (Invitrogen), using 50 nM
siRNA 48 h before viral infections or harvesting for real
time quantitative PCR gene target silencing studies. All
macrophage transfections were performed with Oligo-
fectamine (Invitrogen) using 50 nM siRNA 48 h prior to
infection following the manufacturer’s recommenda-
tions, unless otherwise noted.
Real time quantitative PCR
P r i m e r sa n dp r o b e sf o rr e a lt i m eP C Rw e r ec u s t o m
ordered from Sigma-Aldrich. Full genomic DNA was
isolated from monocyte-derived macrophages or cell
lines using the Qiagen Blood and Tissue Kit. Small non-
genomic DNA, such as reverse transcribed viral cDNA
and 2-LTR circles were isolated using a Qiagen Mini-
prep kit. To detect full length HIV DNA, primers M667
(5’-GGC TAA CTA GGG AAC CCA CTG-3’)a n d
M661 (5’-CCT GCG TCG AGA GAG CTC CTC TGG-
3’) [79], along with probe MH603 (5’-(FAM)-ACA
CTA CTT GAA GCA CTC AAG GCA AGC TTT-
(TAMRA)-3’)[ 8 0 ]w e r eu s e d .T h ep r i m e r su s e dt o
amplify HIV-1 cDNA span the primer binding site
(PBS); the only time there is contiguous DNA on both
sides of the PBS is when synthesis of both full strands
of viral DNA is completed [29,79]. To identify 2-LTR
circle formation, primers MH535 (5’-AAC TAG GGA
ACC CAC TGC TTA AG-3’) and MH536 (5’-TCC
ACA GAT CAA GGA TAT CTT GTC-3’)w e r eu s e d
with the MH603 probe [80]. For integration, a two-step
PCR reaction was performed. For the initial PCR ampli-
fication, Alu forward, (5’-GCC TCC CAA AGT GCT
GGG ATT ACA G-3’); and HIV-1 gag reverse, (5’-GCT
CTC GCA CCC ATC TCT CTC C-3’) primers were
used [81]. The second step real-time PCR used the pri-
mers LTR forward, (5’-GCC TCA ATA AAG CTT GCC
TTG A-3’); and LTR reverse, (5’-TCC ACA CTG ACT
AAA AGG GTC TGA-3’); and LTR probe (5’-FAM-
GCG AGT GCC CGT CTG TTG TGT GAC TCT
G G TA A CT A GC T CG C - D B H 1 - 3 ’)[ 8 1 ] .S e r i a l
dilutions of purified HIV-SX plasmids were used to gen-
erate a standard curve to calculate the total concentra-
tion of HIV-1 cDNA in each sample, which is expressed
as total fentograms (fg) of cDNA. Total mRNA was iso-
lated from siRNA-transfected cells and primary human
macrophages using RNeasy Mini Kits (Qiagen, Inc.,
Valencia, CA). ADAM10 specific primers and probe
were purchased from Applied Biosytems (Carlsbad, CA).
All reactions were performed using Applied Biosystems
TaqMan Universal Master Mix and run using an
Applied Biosystems 7500 Fast Real Time PCR system
and 7500 Fast System Software [33]. Silencing of target
genes was determined by normalizing target gene
expression to GAPDH expression (n = 3).
Flow cytometry
ADAM10 protein expression was assessed using
an analytical flow cytometer in control or ADAM10
siRNA-transfected TZM -bl cells after 48 h. ADAM10
expression in siRNA transfectants was determined by
detaching cells in PBS/2 mM EDTA and staining cells
using either a mouse anti-human ADAM10 antibody
(R&D Systems, Minneapolis, MN) or an IgG1 isotype
control (Southern Biotech, Birmingham, AL), followed
by incubation with a phycoerythrin-conjugated rabbit
anti-mouse secondary antibody (Jackson ImmunoRe-
search, West Grove, PA).
HIV-1 p24 assays
To determine the effect of silencing cellular genes on
HIV-1 replication, TZM-bl cells or primary human
macrophages were transfected with siRNA SMARTpools
for 48 h prior to infection. TZM-bl cells were seeded
into T25 flasks (750,000 cells/flask) and transfected as
described above. Subsequently, cells were infected over-
night with HIV LAV (MOI = 1) and then seeded into
duplicate T75 flasks (1.5 million cells per flask). p24 pro-
duction was assayed from culture supernatants 3 days
post-inoculation using the p24 antigen ELISA system
(Beckman/Coulter/Immunotech, Brea, CA) following the
manufacturer’s protocol. Macrophages were infected in
24-well plates with HIV-SF162, and p24 production was
assayed from cell lysates and culture supernatants 4 and
7 days, respectively, post-infection using p24 Capture
ELISA (ImmunoDiagnostics, Woburn, MA).
b-galactosidase assays
U373-MAGI-CCR5 cells were transfected with ADAM10
or control siRNAs for 48 h, and Tat was expressed by
either infection with HIV-SF162 or transfection with a
pcDNA3-HIV Tat101-Flag vector (NIH Research and
Reference Reagent Program) overnight. At various time
points following infection or transfection, cells were
lysed and analyzed for b-galactosidase activity using the
Friedrich et al. Retrovirology 2011, 8:32
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Bio-Tek Clarity Microplate Luminometer (pcDNA3-HIV
Tat101 Flag transfections) or Dynex MLX Luminometer
(SF162 infections).
DNA plasmid transfections
TZM-bl cells were seeded in 24 well plates at 2 × 10
4
cells/well, and transfected with 800 ng HIV-SX plasmid
DNA using Lipofectamine LTX transfection reagent
(Invitrogen) along with Plus reagent (Invitrogen) using
the one tube protocol according to manufacturer’ss p e -
cifications. After three days incubation, p24 was mea-
sured by using a p24 Capture ELISA (see above).
Transfection of ADAM10 plasmids (wild type and
E384A) was performed using Lipofectamine 2000 (Invi-
trogen) according to manufacturer’s protocols. ADAM10
E384A has a point mutation in its metalloprotease
domain, rendering it inactive. U373-MAGI-CCR5 cells
were plated in 12-well plates. After plasmid transfection,
cells were incubated for 48 h and were then infected with
HIV-SF162 (MOI = 0.1). Forty-eight hours after infection,
a b-galactosidase assay was used to measure infection in
the cells as described above.
Cell toxicity assays
The toxicity of siRNA treatment was measured by
aCella-Tox bioluminescence Cytotoxicity Assay (Cell
Technology Inc, Mountain View, CA), which detects
secreted Glyceraldehyde-3-Phosphate Dehydrogenase
(GAPDH) in cells with diminished membrane integrity.
Values for released GAPDH were normalized to cellular
GAPDH levels.
Statistics
All statistics were performed using a two-tailed, paired
Student’s T-Test (*P < 0.05, **P < 0.01).
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